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Hepatitis B and C virus infection and 
diabetes mellitus: A cohort study
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The role of hepatitis virus infection in glucose homeostasis is uncertain. We examined the associations 
between hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and the development of diabetes 
in a cohort (N = 439,708) of asymptomatic participants in health screening examinations. In cross-
sectional analyses, the multivariable-adjusted odds ratio for prevalent diabetes comparing hepatitis 
B surface antigen (HBsAg) (+) to HBsAg (−) participants was 1.17 (95% CI 1.06–1.31; P = 0.003). The 
corresponding odds ratio comparing hepatitis C antibodies (HCV Ab) (+) to HCV Ab (−) participants 
was 1.43 (95% CI 1.01–2.02, P = 0.043). In prospective analyses, the multivariable-adjusted hazard 
ratio for incident diabetes comparing HBsAg (+) to HbsAg (−) participants was 1.23 (95% CI 1.08–1.41; 
P = 0.007). The number of incident cases of diabetes among HCV Ab (+) participants (10 cases) was too 
small to reliably estimate the prospective association between HCV infection and diabetes. In this large 
population at low risk of diabetes, HBV and HCV infections were associated with diabetes prevalence 
and HBV infection with the risk of incident diabetes. Our studies add evidence suggesting that diabetes 
is an additional metabolic complication of HBV and HCV infection.
Chronic viral hepatic infections are a major threat to public health worldwide. Chronic hepatitis B virus (HBV) 
and hepatitis C virus (HCV) are the leading causes of cirrhosis and hepatocellular carcinoma, two conditions with 
increasing mortality and burden of disease especially in the developing countries1, 2. As the liver has a key role in 
glucose metabolism and adequate liver function is essential to maintain glucose homeostasis3, 4, diabetes may be 
a complication of end-stage liver disease, especially in patients with chronic HCV infection4–7. Since diabetes is 
another major concern in public health, it is very important to establish if chronic viral hepatitis is associated with 
an increased risk of diabetes prior to the development of end-stage liver disease.
The association between positive serology for hepatitis B surface antigen (HBsAg) and incident diabetes has 
been studied in only a few longitudinal studies5, 8, 9, that found no significant associations. Cross-sectional studies 
have also shown no association between positive serology for HBsAg and diabetes10, 11, although the number of 
participants in these studies was small and they had varying degrees of HBV-related liver disease. On the other 
hand, the presence of HCV antibodies (HCV Ab) appears to increase the risk of both incident and prevalent dia-
betes6, 7, 10–14, although many of these studies were not prospective6, 7, 11, 14, had small sample sizes7, 12, 13, or included 
cases with liver cirrhosis which, by itself, can increase the risk of diabetes14. We thus examined the prospective 
association between HBsAg (+) or HCV Ab (+) and incident diabetes in a large cohort of asymptomatic subjects 
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who participated in health screening examinations. In addition to the prospective associations, we also evaluated 
the cross-sectional associations of hepatitis virus infection and prevalent diabetes at baseline for comparability 
with previous studies.
Materials and Methods
Study population. The Kangbuk Samsung Health Study is a cohort study of all adults who underwent a 
comprehensive annual or biennial health screening exam at the Kangbuk Samsung Hospital Total Healthcare 
Screening Centers in Seoul and Suwon, South Korea15, 16. Regular health screening exams are mandated for 
employees by the South Korea Industrial Safety and Health Law. Over 80% of participants in the study were 
employees in a company that contracted the routine health screening exams with the Kangbuk Samsung Hospital 
or their relatives. The rest of participants voluntarily purchased health screening exams.
Our study had two components. First, we conducted a cross-sectional analysis of the association between 
HBsAg or HCV Ab and prevalent diabetes among all participants 18 to 70 years of age who underwent a com-
prehensive screening exam between January 1, 2002 and December 31, 2013 (n = 453,956). For this analysis, we 
excluded participants with ultrasonographic evidence of malignancy in the liver (n = 289), history of liver surgery 
or liver transplantation (n = 126), and history of any cancer, including hepatocellular carcinoma (n = 6,271). 
We further excluded participants with missing data on fasting glucose (n = 17), HBsAg (n = 173) or HCV Ab 
(n = 7,533). The final sample size included in the cross-sectional analysis was 439,708 (237,662 men and 202,046 
women). Second, we conducted a cohort analysis of the association between HBsAg or HCV Ab and the devel-
opment of incident diabetes among the 219,448 study participants (127,985 men and 91,463 women) without 
prevalent diabetes at baseline who had at least one follow-up screening exam prior to December 31, 2013.
We have obtained informed consent for participation from study participants starting year 2010. The 
Institutional Review Board (IRB) of the Kangbuk Samsung Hospital, which approved the study, waived the 
requirement for informed consent as we used only de-identified data that were collected as part of routine health 
screening exams. All methods were performed according to the local guidelines and regulations.
Measurements. At each screening visit, study participants provided information on medical history, family 
history, use of medication, smoking habits, alcohol consumption, physical activity, and education level using 
a standardized self-administered questionnaire. Smoking status was categorized as never, former, and current. 
Alcohol intake was estimated in g/day and was categorized to none, moderate (≤30 g/day for males, ≤20 g/day for 
females), and high (>30 g/day for males, >20 g/day for females). Vigorous physical activity was categorized as <3 
or ≥3 days per week. Education level was categorized as less than or equal to 12 years of education or more than 
12 years of education. Participants who reported any first-degree relative with diabetes were classified as having a 
family history of diabetes. Anthropometric parameters and blood pressure were measured by trained staff mem-
bers. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg/m2).
Blood specimens were sampled from the antecubital vein after at least 10 hours of fasting. Liver enzymes, 
including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase 
(GGT), and serum fasting glucose were measured using Bayer Reagent Packs on an automated chemistry ana-
lyzer (Advia 1650TM Autoanalyzer; Bayer Diagnostics, Medfeld, MA, USA) between 2002 and February 2010 
at the Seoul center and between 2002 and September 2006 at the Suwon center, and using a Modular Analytics 
D2400 (Roche Diagnostics, Tokyo, Japan) afterwards. The presence of HBsAg and HCV Ab was determined 
using immunoradiometric assays (Radim, Via del Mare, Italy) in the Seoul center from 2002 to 2009 and in the 
Suwon center from 2002 to 2006, and using electrochemiluminescent immunoassays (Modular E170; Roche 
Diagnostics) since 2010 in the Seoul center and since 2007 in the Suwon center. Diabetes was defined as the 
presence of self-reported physician diagnosis, self-reported current use of insulin or other hypoglycemic agent, 
or fasting serum glucose ≥126 mg/dl. The Laboratory Medicine Department at Kangbuk Samsung Hospital has 
been accredited by the Korean Society of Laboratory Medicine (KSLM) and the Korean Association of Quality 
Assurance for Clinical Laboratories (KAQACL). The laboratory also participates in the survey proficiency testing 
provided by the College of American Pathologists (CAP).
Abdominal ultrasonography was performed by experienced radiologists with a Logic Q700 MR 3.5-MHz 
transducer (GE, Milwaukee, WI, USA). A diagnosis of fatty liver disease on ultrasonography was based on the 
presence of diffuse hyperechoic parenchyma compared to that of the kidney or spleen17. A diagnosis of cirrhosis 
on ultrasonography was based on the presence of coarse and inhomogeneous parenchyma, caudate hypertrophy, 
surface nodularity, signs of portal hypertension, or regenerative nodules.
Statistical analysis. Demographic characteristics, liver function profiles, serum fasting glucose level and 
the presence of hypertension, diabetes, and fatty liver disease at baseline visit were compared by HBsAg and HCV 
Ab status. Categorical variables were summarized as number (proportion), and continuous variables as mean 
(standard deviation) or median (interquartile range). Among the continuous variables compared, alcohol intake, 
ALT, AST, and GGT exhibited non-symmetrical distribution. Comparisons were made using a chi-square test, 
Student’s t-test, or Kruskal-Wallis test, as needed.
For cross-sectional analyses, we calculated odds ratios and 95% confidence intervals (CI) for prevalent diabe-
tes by HBsAg or HCV Ab status using logistic regression. We used 3 models with progressive degrees of adjust-
ment. Model 1: adjusted for age, sex, and center; Model 2: further adjusted for cigarette smoking, alcohol intake, 
education, physical activity and BMI; and Model 3: further adjusted for the presence of fatty liver disease on 
ultrasound.
For prospective analyses, we examined the association between HBsAg or HCV Ab status and incident dia-
betes. We restricted these analyses to participants without diabetes at baseline. For each individual, follow up 
extended from baseline until the development of diabetes or until the last screening visit. Because the exact date 
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of the onset of diabetes occurs between two screening visits and is unknown, we used a parametric proportional 
hazards model to take into account this type of interval censoring (stpm command in Stata)18. The baseline hazard 
function was parametrized with restricted cubic splines in log time with four degrees of freedom. Hazard ratios 
and 95% CI for incident diabetes by HBsAg or HCV Ab status were obtained from 3 models: Model 1: adjusted 
for age, sex, and center; Model 2: further adjusted for cigarette smoking, alcohol intake, education, physical activ-
ity, BMI, and presence of fatty liver disease on ultrasound; and Model 3: further adjusted for the baseline fasting 
glucose level.
There were 35 participants who were HBsAg (+) and HCV Ab (+) at baseline, among 439,708 participants 
included in the cross-sectional analyses. Among 219,448 participants who were included in the prospective anal-
yses of the study, there were 18 participants who were positive for both HBsAg and HCV antibody. Because the 
concomitant presence of HBsAg and HCV Ab may affect the development of diabetes, the same cross-sectional 
and prospective analyses were performed in a population restricted to a single exposure of HBsAg or HCV Ab.
All statistical analyses were performed with STATA version 12.0 (StataCorp LP, College Station, Texas). P 
values reported in the study are two-sided and P values < 0.05 were considered statistically significant.
Data availability. The data that support the findings of this study are available from the Kangbuk Samsung 
Health Study and the corresponding authors upon request. The data are not publicly available as we do not have 
IRB approval for distribution of the data.
Results
Cross-sectional analysis. The cross-sectional analysis included 439,708 participants with a mean (SD) age 
of 39.4 (9.8) years and 54.1% of the population was male (Table 1). The prevalence of HBsAg (+) and HCV Ab 
(+) participants was 3.8 and 0.2%, respectively. Thirty-five participants were positive for both HBsAg and HCV 
Ab at baseline. HBsAg (+) and HCV Ab (+) participants were both more likely to be older, to have a higher BMI 
and higher levels of liver enzymes, and to consume less alcohol. The prevalence of fatty liver disease was higher in 
seropositive participants than in seronegative participants.
The prevalence of diabetes was 3.8% (n = 16,485). Compared to participants without diabetes, those with 
diabetes were more likely to be older, male, and current smokers. Also, participants with diabetes at baseline 
had higher proportion of family history of diabetes and fatty liver disease (Supplement Table 1) compared to 
those without diabetes. Participants with diabetes also had higher levels of BMI and liver enzymes and a lower 
frequency of education level more than 12 years.
The crude (unadjusted) prevalence of diabetes was similar in participants with and without HBsAg (3.8% in 
both groups). After adjusting for age, sex, center, smoking, alcohol intake, education, physical activity, BMI, and 
presence of fatty liver, the odds ratio for prevalent diabetes comparing HBsAg (+) to HBsAg (−) participants 
was 1.17 (95% CI 1.06–1.31; P = 0.003; Table 2). The odds ratio was unchanged after excluding participants with 
cirrhosis diagnosed using ultrasound (n = 160; odds ratio 1.17, 95% CI 1.05–1.30, P = 0.004).
The unadjusted prevalence of diabetes was higher in HCV Ab (+) participants compared to HCV Ab (−) par-
ticipants (8.7% vs. 3.7%, P < 0.001). In the multivariable-adjusted model (Model 3), the odds ratio for prevalent 
diabetes comparing HCV Ab (+) to HCV Ab (−) participants was 1.43 (95% CI 1.01–2.02, P = 0.043; Table 2). 
Characteristics Overall
Hepatitis B virus infection
P value
Hepatitis C virus infection
P valueHBsAg (−) HBsAg (+) HCV Ab (−) HCV Ab (+)
Number (%) 439,708 423,001 (96.2) 16,707 (3.8) 438,924 (99.8) 784 (0.2)
Age, years* 39.4 (9.8) 39.4 (9.9) 40.1 (9.2) <0.001 39.4 (9.8) 48.7 (11.6) <0.001
Men, % 54.1 53.8 61.2 <0.001 54.1 48.7 0.003
Current smoker, % 25.2 25.2 27.1 <0.001 25.2 24.4 <0.001
Alcohol intake, g/day† 5 (0–15) 5 (0–15) 3 (0–13) <0.001 5 (0–15) 3 (0–14) <0.001
Vigorous exercise, %‡ 15.1 15.1 16.2 <0.001 15.1 20.2 <0.001
12+ years of 
education, %§ 49.4 49.4 49.2 0.63 49.4 33.2 <0.001
BMI, kg/m2* 23.4 (3.2) 23.3 (3.2) 23.6 (3.2) <0.001 23.4 (3.2) 23.9 (3.1) <0.001
ALT, U/l† 20 (14–29) 20 (14–29) 26 (19–39) <0.001 20 (14–29) 30 (18–50) <0.001
AST, U/l† 21 (18–26) 21 (18–26) 25 (21–32) <0.001 21 (18–26) 29 (22–41) <0.001
GGT, U/l† 19 (12–34) 19 (12–34) 20 (13–35) <0.001 19 (12–34) 23 (15–42) <0.001
Glucose, mg/dl* 94.6 (16.4) 94.7 (16.3) 94.2 (17.0) <0.001 94.6 (16.3) 99.6 (26.0) <0.001
Prevalent diabetes, % 3.8 3.8 3.8 0.60 3.7 8.7 <0.001
Family history of 
DM, % 14.7 14.8 13.0 <0.001 14.7 13.7 0.39
USG Fatty liver 
disease, % 26.5 26.7 23.0 <0.001 26.6 21.3 0.001
Table 1. Participant characteristics by hepatitis virus infection at baseline in cross-sectional analysis 
(n = 439,708). Values are *means (standard deviation), †medians (interquartile range), or percentages. ‡≥3 
times per week. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body 
mass index; DM, diabetes mellitus; GGT, gamma-glutamyl transferase; USG, ultrasonography.
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After excluding participants with cirrhosis (n = 160), the odds of prevalent diabetes was 1.4 times higher in HCV 
Ab (+) participants compared to HCV Ab (−) participants (95% CI 0.98–1.98, P = 0.06).
When the study population was restricted to HCV Ab (−) participants (n = 438,924), HBsAg (+) participants 
had 18% higher odds (95% CI 1.06–1.31, P = 0.003) of prevalent diabetes compared to HBsAg (−) counterparts 
(Supplement Table 2) in the fully-adjusted model. In a study population restricted to HBsAg (−) participants 
(n = 423,001), the adjusted odds ratio of prevalent diabetes between HCV Ab (+) and HCV Ab (−) participants 
was 1.51 (95% CI 1.06–2.13, P = 0.02).
Prospective analysis. The characteristics of the 219,448 participants included in the prospective analyses 
were similar to those in the cross-sectional analysis (Supplement Table 3). The average duration of follow-up 
was 4.8 years (maximum follow-up 11.7 years). We observed 7,491 incident cases of diabetes over 1,059,666.3 
person-years of follow-up. Most risk factors for incident cases of diabetes were similar to those for prevalent cases. 
Of note, although all participants had within-normal range fasting glucose level (<126 mg/dl), those with higher 
baseline levels of glucose were more likely to develop incident diabetes (Table 3).
The number of incident cases of diabetes among 8,694 HBsAg (+) participants and among 210,754 HBsAg 
(−) participants were 303 and 7,188, respectively (Table 4). In models adjusted for age, sex, center, smoking, 
alcohol intake, education, physical activity, BMI, presence of fatty liver and fasting glucose levels at baseline, 
the hazard ratio for incident diabetes comparing HBsAg (+) to HbsAg (−) participants was 1.20 (95% CI 1.05–
1.37; P = 0.007). After excluding participants with cirrhosis diagnosed at baseline using ultrasound (n = 57), the 
multivariable-adjusted hazard ratio was 1.20 (95% CI 1.05–1.37, P = 0.007).
Hepatitis virus 
infection
Prevalent 
diabetes N (%)
Model 1 OR (95% 
CI)
Model 2 OR (95% 
CI)
Model 3 OR (95% 
CI)
HBsAg
Negative 15,846 (3.8) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Positive 639 (3.8) 0.98 (0.90–1.07) 1.03 (0.93–1.15) 1.17 (1.06–1.31)
P Value 0.68 0.52 0.003
HCV Ab
Negative 16,417 (3.7) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Positive 68 (8.7) 1.07 (0.82–1.39) 1.14 (0.81–1.60) 1.43 (1.01–2.02)
P Value 0.62 0.47 0.043
Table 2. Odds ratios for prevalent diabetes by hepatitis virus infection at baseline (n = 439,708). Model 1: 
adjusted for age, sex, and center; Model 2: further adjusted for smoking (never, former and current), alcohol 
(none, moderate and high), education (≤12 years or >12 years of education), physical activity (<3 times/week 
and ≥3 times/week), and BMI (continuous); Model 3: further adjusted for presence of fatty liver disease.
Characteristics
Incident diabetes
P valueNo Yes
Number 211,957 7,491
Age, years* 37.4 (7.6) 41.5 (8.5) <0.001
Men, % 57.6 78.7 <0.001
Current smoker, % 26.9 39.1 <0.001
Alcohol intake, g/day† 5 (0–14) 8 (0–19) <0.001
Vigorous exercise, %‡ 14.8 17.2 <0.001
12+ years of education, %§ 78.1 69.7 <0.001
BMI, kg/m2* 23.2 (3.1) 25.7 (3.2) <0.001
ALT, U/l† 20 (14–29) 31 (21–48) <0.001
AST, U/l† 21 (18–26) 26 (21–33) <0.001
GGT, U/l† 19 (12–32) 37 (22–63) <0.001
Glucose, mg/dl* 92.0 (8.3) 104.4 (10.9) <0.001
Family history of DM, % 14.0 22.9 <0.001
USG Fatty liver disease, % 23.8 58.5 <0.001
HBsAg (+), % 4.0 4.0 0.71
HCV Ab (+), % 0.1 0.1 0.91
Table 3. Baseline participant characteristics by incidence of diabetes in cohort analysis (n = 219,448). 
Values are *means (standard deviation), †medians (interquartile range), or percentages. ‡≥3 times per week. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DM, 
diabetes mellitus; GGT, gamma-glutamyl transferase; USG, ultrasonography.
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The number of incident cases of diabetes among 283 HCV Ab (+) participants and among 219,165 HCV Ab 
(−) participants were 10 and 7,481 (Table 4). The multivariable-adjusted hazard ratio for incident diabetes com-
paring HCV Ab (+) and HCV Ab (−) participants was 0.75 (95% CI 0.31–1.81; P = 0.52). The hazard ratio was 
unchanged after excluding participants with cirrhosis diagnosed using ultrasound at baseline.
In a study population restricted to HCV Ab (−) participants (n = 219,165), HBsAg (+) participants 
had 20% higher hazard (95% CI 1.05–1.37, P = 0.008) of incident diabetes compared to HBsAg (−) partici-
pants (Supplement Table 4) in the multivariable-adjusted model. When restricted to HBsAg (−) participants 
(n = 210,754), the adjusted hazard ratio for incident diabetes between HCV Ab (+) and HCV Ab (−) participants 
was 0.77 (95% CI 0.32–1.86, P = 0.57).
Since serological evaluation of HBV and HCV infection was included as a routine part of the blood work in 
all health exams in our cohort, we could also determine participants who maintained their serologic status over 
follow-up. Among 8,694 participants who were HBsAg (+) at baseline, there were 535 participants who converted 
to HBsAg (−) over time, and among 210,754 participants who were who were initially HBsAg (−), 28 partici-
pants converted to HBsAg (+). Among 283 participants who were HCV Ab (+) at baseline, 59 of them converted 
to HCV Ab (−), and among 219,165 participants who were initially HCV Ab (−), 77 converted to HCV Ab (+). 
In fully-adjusted models restricted to participants who did not change serologic status over time, the hazard ratio 
for incident diabetes comparing HBsAg (+) to HBsAg (−) participants was 1.24 (95% CI 1.08–1.43; P = 0.002), 
and the corresponding hazard ratio for comparing HCV Ab (+) to HCV Ab (−) participants was 0.78 (95% CI 
0.32–1.86; P = 0.57).
Discussion
In this large study of healthy men and women, we found a cross-sectional association of HBV and HCV infec-
tion with the prevalence of diabetes. The association was stronger for HCV compared to HBV. The associations 
were evident even after excluding participants with cirrhosis on ultrasound exam. For HBV, the association was 
also observed in a prospective analysis of participants who did not have diabetes at baseline. We did not find an 
association between HCV infection and the risk of diabetes in prospective studies, but the number of incident 
cases among HCV Ab (+) was too small to obtain reliable risk estimates. Our study adds novel evidence on a 
prospective association of HBV infection and the risk of incident diabetes and adds to the evidence that hepatitis 
virus infection is linked to the development of glucose metabolism abnormalities.
The association between HBV infection and diabetes has been controversial. The prevalence of diabetes was 
higher in HBsAg (+) compared to HBsAg (−) patients in some studies19–21, but not in others7, 10. In a 10-year 
prospective study restricted to subjects without cirrhosis, HBV infection was not associated with the incidence of 
diabetes or glucose intolerance8, but this study was limited by a small sample size. In the present study, the large 
sample size, the use of careful laboratory methods to assess incident diabetes, and the ability to adjust for multiple 
baseline covariates, including the presence of fatty liver disease, allowed us to identify a clear association between 
HBsAg and diabetes in both cross-sectional and incident analyses.
With respect to HCV, our finding of an association between HCV Ab (+) and diabetes are consistent 
with most previous studies. In a meta-analysis of 17 studies comparing HCV-infected participants to HCV 
non-infected participants, the pooled OR for diabetes was 1.6822. In our study, the cross-sectional association 
between HCV infection and diabetes was identified even though the prevalence of HCV Ab (+) participants in 
our study was lower compared to that of other studies and the overall risk of diabetes in our study population was 
low because of young age and low BMI. This finding thus confirms that HCV virus infection can be a risk factor 
for diabetes even in low risk populations.
Given the pivotal role of the liver in glucose metabolism3, 4, the presence of severe hepatic diseases, such as 
liver cirrhosis and hepatocellular carcinoma, leads to dysregulation in glucose homeostasis4, 17, 23. The mechanisms 
underlying the disruption in glucose metabolism in the context of viral hepatitis without cirrhosis, however, is 
unclear14, 24–26. In one study, patients with either chronic HBV or HCV infection with elevated liver enzymes 
showed a strong association between the extent of fibrosis in liver biopsies and diabetes, but without differences 
Hepatitis virus 
infection
No. of incident 
cases Person-years
Model 1 HR (95% 
CI)
Model 2 HR (95% 
CI)
Model 3 HR (95% 
CI)
HBsAg
Negative 7,188 1,016,231.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
Positive 303 43,435.1 0.91 (0.81–1.02) 1.07 (0.94–1.22) 1.20 (1.05–1.37)
P Value 0.10 0.31 0.007
HCV Ab
Negative 7,481 1,058,402.5 1.00 (reference) 1.00 (reference) 1.00 (reference)
Positive 10 1,263.8 0.77 (0.42–1.44) 0.72 (0.30–1.73) 0.75 (0.31–1.81)
P Value 0.42 0.46 0.52
Table 4. Hazard ratios for incident diabetes by hepatitis virus infection status (n = 219,448). Model 1: adjusted 
for age, sex, and center; Model 2: further adjusted for smoking (never, former and current), alcohol (none, 
moderate and high), education (≤12 years or >12 years of education), physical activity (<3 times/week and ≥3 
times/week), BMI (continuous), and presence of fatty liver disease; Model 3: further adjusted for initial fasting 
glucose level.
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between HBV and HCV infection21. An Italian group also found cirrhosis and age to be the only two factors inde-
pendently associated with the presence of diabetes in patients with chronic HCV infection27.
Other mechanisms have been suggested to explain altered glucose metabolism in HCV infection. In experi-
mental studies HCV can directly disturb the insulin signaling cascade in infected hepatocytes28, 29, which may be 
driven by genotype-specific pathways30. HCV may also interfere with glucose metabolism indirectly by causing 
peripheral insulin resistance in muscle tissue of chronic HCV patients31. The effect of HBV infection on the devel-
opment of diabetes is less understood and has been mostly attributable to HBV-related cirrhosis32. Additional 
research is needed to understand the mechanisms involved in altered glucose metabolism in HBV and HCV 
patients.
Although we had a large sample size and implemented both cross-sectional and longitudinal study designs, 
there are a few limitations. First, the number of participants with HCV Ab in the study was relatively small 
(0.18%). The prevalence of HCV Ab (+) in the general Korean adult population ranges from 0.5 to 1.0% with the 
highest prevalence in those over 60 years of age33, 34. The prevalence in of HCV Ab (+) in Korea is low by global 
standards (global estimates of prevalence 2.35%)35. In our study, we observed a clear association between HCV 
Ab (+) and prevalent diabetes even though our population was at low risk of both HCV and diabetes and was 
comprised of relatively young, healthy, and low BMI participants. Unfortunately, we were unable to confirm this 
association in prospective analysis because there were only 10 cases of incident diabetes among HCV Ab (+) 
participants during follow-up (The power of our study to detect relative risks for diabetes of 1.10, 1.20, and 1.30 
when comparing HCV Ab (+) to HCV Ab (−) participants was 6.1, 9.4, and 14.8%, respectively).
Second, diabetes was defined based on self-reported medical history, medication history, and a single meas-
urement of fasting serum glucose, which is a commonly used definition in epidemiologic studies but differs from 
clinical diagnostic criteria for diabetes36. Our definition will introduce some degree of misclassification of the 
outcome status, but this type of misclassification is likely to be non-differential and, therefore, would induce an 
attenuation of the association. In addition, we cannot distinguish between cases of type 1 and type 2 diabetes in 
our data. However, we expect that most new cases of diabetes occurring in this cohort are type 2 diabetes because 
the participants in this cohort were adults (mean age 39.4 years) and we excluded participants with diabetes at 
baseline.
Third, study participants were followed for a maximum of 12 years (average duration of follow-up 4.8 years). It 
is possible that the full effects of hepatitis virus infection on diabetes and glucose metabolism take longer to man-
ifest in chronically infected patients. Further longitudinal studies with longer duration of follow-up are needed 
to fully characterize the effects of hepatitis virus infection on the risk of diabetes. Fourth, although ultrasound 
is a well-established, widely-used non-invasive modality to diagnose liver cirrhosis in population studies, its 
sensitivity and specificity to detect liver cirrhosis are imperfect (sensitivity 54–84%, specificity 80–100%, positive 
predictive value 68–87%, and negative predictive value 36–42%)37, 38. Therefore, some cases of liver cirrhosis may 
have been misdiagnosed and included in our sensitivity analyses. Fifth, the level and frequency of physical activity 
was measured using a self-reported questionnaire, which may not be the most accurate method to assess physical 
activity and can be subject to some misclassification. Finally, the study was conducted among participants attend-
ing routine health exams and may not be generalizable to other populations or ethnic groups.
In conclusion, in this large study of men and women at low risk of diabetes, we found that serologic evidence 
of HBV and HCV infection was associated with the prevalence of diabetes. In addition, HBV infection was asso-
ciated with the risk of incident diabetes in prospective analyses, but we could not reliably evaluate the prospective 
association between HCV infection and diabetes due to the small number of infected participants. Our studies 
add to the growing body of evidence suggesting that diabetes is an additional metabolic complication of HBV 
and HCV infection.
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